Multiple Myeloma Coverage from Every Angle

FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma

By: Jocelyn Solis-Moreira, MS
Posted: Thursday, August 6, 2020

On August 5, the U.S. Food and Drug Administration (FDA) approved the antibody drug-conjugate belantamab mafodotin-blmf (Blenrep) for treatment of adults with relapsed or refractory multiple myeloma. Drug eligibility includes patients who have had four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Earlier in July, an FDA panel voted unanimously in favor of approving belantamab mafodotin for multiple myeloma treatment.

Belantamab mafodotin-blmf is the first anti–B-cell maturation antigen therapy approved anywhere in the world. The recommended dose for belantamab mafodotin-blmf is 2.5 mg/kg as an intravenous (IV) infusion over approximately 30 minutes once every 3 weeks.

The accelerated FDA approval was based on data from the open-label, multicenter DREAMM-2 study. Patients with multiple myeloma were given either 2.5 mg/kg or 3.4 mg/kg of IV belantamab mafodotin-blmf every 3 weeks until disease progression or unacceptable toxicity. Patients with a median of seven prior lines of treatment showed a clinically meaningful overall response rate of 31% (97.5% confidence interval = 21%–43%). In addition, 73% of patients with a response had a response duration over 6 months. Although the median duration of response was not reached, 73% of responders had a duration of response of at least 6 months.

About 20% or more of patients taking belantamab mafodotin-blmf reported adverse events, with 77% of patients in the study experiencing ocular adverse reactions (keratopathy, changes in visual acuity, blurred vision, and dry eyes). About 2% of patients in the 2.5-mg/kg cohort discontinued treatment because of keratopathy. Other common adverse events were pyrexia, infusion-related reactions, fatigue, and nausea.

For prescribing information on belantamab mafodotin-blmf, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.